ArticleScientific reports2025
Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The present study investigated the formulation, development, and characterization of Fosfomycin pessaries for the treatment of genitourinary tract infections. To achieve higher local concentration and to avoid the systemic exposure of the body towards Fosfomycin, vaginal pessaries have been developed in this research work. Methodology The Fosfomycin pessaries were prepared using the hand rolling method. After the formulation of the Fosfomycin pessaries, pre-formulation studies were conducted to evaluate the drug-excipient compatibility, followed by in vivo studies. Results The pre-formulation studies using FTIR (Fourier Transform Infra-Red) spectrophotometric analysis showed no significant interaction of Fosfomycin with the base and formation of Fosfomycin pessaries. Furthermore, DSC (differential scanning calorimetry) and TGA (thermogravimetric analysis) analysis confirm the formulation stability. The physicochemical analysis of Fosfomycin pessaries, including liquefaction time and breaking force, showed the formulation within the pharmacopeia standard range. Furthermore, the pharmacokinetic and in vitro release studies showed that Fosfomycin pessaries, in contrast to the Fosfomycin suspension, exhibited higher elimination time, higher absorption rate, and area under the curve. The antibacterial results of the Fosfomycin pessaries showed significant activity against E. coli using in vitro and in vivo studies. Conclusion The in vitro and in vivo results revealed that Fosfomycin pessaries have improved pharmacokinetics and increased antibacterial activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.